Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, et al. N Engl J Med 2022;386:24-34.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 2022;386:24-34.
PMID: 34986285